低剂量糖皮质激素治疗成人脓毒性休克:系统评价与荟萃分析及试验序贯分析
该系统评价纳入22项随机临床试验、共7297例成人脓毒性休克患者,比较低剂量糖皮质激素与安慰剂。两项低偏倚风险试验中,短期死亡率RR 0.98(95%CI 0.89-1.08,P=0.71),全部试验敏感性分析RR 0.96(95%CI 0.91-1.02,P=0.21),长期死亡率RR 0.96(95%CI 0.90-1.02,P=0.18)。低偏倚风险试验中糖皮质激素组任何不良事件风险更高(RR 1.66,95%CI 1.03-2.70,P=0.04,I²=78%)。糖皮质激素缩短休克持续时间(MD -1.52天,95%CI -1.71至-1.32,P<0.0001)、机械通气时间(MD -1.38天,95%CI -1.96至-0.80,P<0.0001)和ICU停留时间(MD -0.75天,95%CI -1.34至-0.17,P=0.01)。
要点
- 低剂量糖皮质激素不降低脓毒性休克成人短期死亡率:低偏倚风险试验RR 0.98(95%CI 0.89-1.08),全部试验RR 0.96(95%CI 0.91-1.02)。
- 长期死亡率亦无改善:RR 0.96(95%CI 0.90-1.02,P=0.18)。
- 低偏倚风险试验中糖皮质激素组任何不良事件风险升高:RR 1.66(95%CI 1.03-2.70,P=0.04),异质性I²=78%。
- 糖皮质激素缩短休克持续时间(MD -1.52天)、机械通气时间(MD -1.38天)和ICU停留时间(MD -0.75天)。
- 无试验报告生活质量结局。
适用人群与场景
- 成人脓毒性休克患者,纳入随机临床试验比较低剂量糖皮质激素与安慰剂。
研究设计与关键结果
- 系统评价与荟萃分析纳入22项随机临床试验,共7297例成人脓毒性休克患者提供短期死亡率数据。
- 两项低偏倚风险试验中,糖皮质激素vs安慰剂短期死亡率RR 0.98(95%CI 0.89-1.08,P=0.71)。
- 全部试验敏感性分析短期死亡率RR 0.96(95%CI 0.91-1.02,P=0.21)。
- 长期死亡率RR 0.96(95%CI 0.90-1.02,P=0.18)。
- 低偏倚风险试验中任何不良事件风险糖皮质激素组更高:RR 1.66(95%CI 1.03-2.70,P=0.04,I²=78%)。
- 休克持续时间MD -1.52天(95%CI -1.71至-1.32,P<0.0001),机械通气时间MD -1.38天(95%CI -1.96至-0.80,P<0.0001),ICU停留时间MD -0.75天(95%CI -1.34至-0.17,P=0.01),均为糖皮质激素vs安慰剂。
- 无试验报告生活质量结局。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析,纳入22项随机临床试验。
- 局限:低偏倚风险试验中不良事件分析存在显著异质性(I²=78%);无试验报告生活质量结局。
对床旁实践的改变
- 作者结论认为,成人脓毒性休克使用低剂量糖皮质激素不改变短期和长期死亡率,不良事件增加,但缩短休克、机械通气及ICU停留时间。
指南或共识出处
- PROSPERO注册号CRD42017084037。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: To assess the effect of low dose corticosteroids on outcomes in adults with septic shock.
METHODS: We systematically reviewed randomised clinical trials (RCTs) comparing low-dose corticosteroids to placebo in adults with septic shock. Trial selection, data abstraction and risk of bias assessment were performed in duplicate. The primary outcome was short-term mortality. Secondary and tertiary outcomes included longer-term mortality, adverse events, quality of life, and duration of shock, mechanical ventilation and ICU stay.
RESULTS: There were 22 RCTs, including 7297 participants, providing data on short-term mortality. In two low risk of bias trials, the relative risk (RR) of short-term mortality with corticosteroid versus placebo was 0.98 [95% confidence interval (CI) 0.89-1.08, p = 0.71]. Sensitivity analysis including all trials was similar (RR 0.96; 95% CI 0.91-1.02, p = 0.21) as was analysis of longer-term mortality (RR 0.96; 95% CI 0.90-1.02, p = 0.18). In low risk of bias trials, the risk of experiencing any adverse event was higher with corticosteroids; however, there was substantial heterogeneity (RR 1.66; 95% CI 1.03-2.70, p = 0.04, I2 = 78%). No trials reported quality of life outcomes. Duration of shock [mean difference (MD) -1.52 days; 95% CI -1.71 to -1.32, p < 0.0001], duration of mechanical ventilation (MD -1.38 days; 95% CI -1.96 to -0.80, p < 0.0001), and ICU stay (MD -0.75 days; 95% CI -1.34 to -0.17, p = 0.01) were shorter with corticosteroids versus placebo.
CONCLUSIONS: In adults with septic shock treated with low dose corticosteroids, short- and longer-term mortality are unaffected, adverse events increase, but duration of shock, mechanical ventilation and ICU stay are reduced. PROSPERO registration no. CRD42017084037.
参考来源
- Rygård SL, Butler E, Granholm A, et al. Low-dose corticosteroids for adult patients with septic shock: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 2018. PMID: 29761216. doi:10.1007/s00134-018-5197-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。